OBJECTIVES:
The aim of this study was to compare the cost effectiveness of BMD-(Bone Mineral Density) screening tools-RA, QUS, pDXA, QCT, and DXA, for women's lifetime bone densitometry exam at 66 years old. METHODS: A total of 101 subjects aged in 60s' were recruited to estimate sensitivity and specificity of each BMD screening tool. A Markov model was developed to analyze the cost-effectiveness of DXA, QUS, RA, pDXA, and QCT. A cohort of 10,000 women aged 66 was constructed for each bone densitometry and a cohort of 10,000 women aged 66 was also constructed as a non-exam group. In the Markov model of osteoporosis and its related fractures, costs and effectiveness measured by QALY were estimated until the cohorts reached 100 years old or died. It was assumed that only costs were discounted by 5% and the compliance for osteoporosis drugs was 38%. Sensitivity analysis was performed on the discount rate and the compliance to osteoporosis drugs. RESULTS: ICER (incremental cost-effectiveness ratio) is an indicator of how much extra costs are needed to increase an extra 1 QALY compared to the reference group. The magnitudes of ICER's were ordered as DXAϽpDXAϽ (QCT, RA, QUS) . DXA and pDXA cost extra 398,618 won and 453,947 won, respectively, in order to increase 1 extra QALY compared to the non-exam group, which meant that DXA and pDXA were very cost-effective. The extra costs for QUS, RA, and QCT to increase 1 QALY compared to the non-exam group ranged 530,000 won'590,000 won, which meant that these were also cost-effective. CONCLUSIONS: All the BMD screening tools that were examined in this study were found to be cost-effective in terms of ICER. When the relative cost-effectiveness of pDXA, QUS, RA, and QCT compared with DXA, DXA was predominant over the other. 
HT3 DEVELOPMENT OF A CHECK LIST FOR QUALITY ASSESSMENT OF PHARMACOECONOMIC EVALUATIONS SUBMITTED FOR REIMBURSEMENT IN TAIWAN

OBJECTIVES:
It is not mandatory for pharmaceutical manufacturers to submit cost-effectiveness evidence yet in Taiwan, but an incentive of a maximum 10% mark-up for conducting local cost-effectiveness analysis has been announced since 2010. HTA/CDE (Division of Health Technology Assessment, Center for Drug Evaluation) assists the assessment on the strength of evidence of local cost-effectiveness evaluation, and a checklist was therefore developed to ensure the consistency and to improve the transparency. This study presents the impact of local pharmacoeconomic incentive and the development of the checklist. METHODS: By reviewing other international checklists for quality assessment of pharmacoeconomic evidence and adding items for local adaptation and transferability, a checklist consisting of four dimensions including PICOS, cost-effectiveness analysis design, source of parameters, and overall quality was developed with a four-levelgrading for evidence strength. The local pharmacoeconomic evidence was identified from the dossiers submitted by the manufacturers during 2008-2011, and was independently assessed by the four reviewers in the economic evaluation team of HTA/CDE as reference cases. Discrepancies between reviewers were discussed until consensus was reached. RESULTS: There were 83 and 67 dossiers submitted for reimbursement before and after the incentive was announced, respectively. However, no local pharmacoeconomic evidence has been submitted until eight months after the incentive was announceed. Another four dossiers consist of five local pharmacoeconomic evaluation (one with multiple indications) were submitted in 2011. The strengths of evidence were graded as strong, medium, low, and very low for 0, 1, 2, and 3 cases according to the checklist. CONCLUSIONS: A pragmatic strategy was used to incorporate cost-effectiveness evidence into the drug reimbursement decisions in Taiwan. Local pharmacoeconomic evidence submissions increase slowly after the incentive was announced. A quality assessment checklist was proposed. Further experience will be cumulated and discussed among the submitting bodies, the appraisal committee members, and HTA/CDE. The analysis revealed the initiated collaboration between HTA stakeholders in the Asia region. In the centre of the Asian HTA ecosystem are located the most established agencies in Korea, Taiwan and Thailand where HTA already yields important evidence to inform policy and practice. The visual analysis revealed patterns of collaboration where agencies were 1) referring to each other; 2) referring to the same sources and academic institutions, and 3) absorbing the experience from well-established European HTA agencies such as NICE or IQWIG. CONCLUSIONS: HTA has expanded globally and can be characterised by common patterns in interactions when looking at and refining the evidence required for the reimbursment. Rapidly growing in number and in influence HTA organizations in Asia are strengthening their abilities through collaboration with each other, by involving independent research institutions into the HTA process and by building upon European HTA experience. METHODS: This prospective study was conducted from July to December 2010 at gastroenterology clinics in a regional hospital in southern Taiwan. IBS outpatients diagnosed by Rome III criteria were invited into participate semi-structure interview survey by using EuroQol (EQ-5D) questionnaire, 100-mm visual analogue scale (EQ-5D VAS) and standard gamble (SG) method. The EQ-5D assessment was transformed into EQ-5D index using Japanese preference weight. Multiple regression was used to assess factors associated with utilities, e.g. demographic, socioeconomic status and disease severity. RESULTS: Of all, 29 participants (mean age 45.8Ϯ16.5 years; 62.1% female) completed QoL survey, except for one rejected SG survey for disagreeing with SG hypothesis. Participants' IBS subtypes include constipation (nϭ11; 37.9%), diarrhea (nϭ16; 55.2%) and unsubtyped IBS (nϭ2; 6.9%); and 12 (41.4%) participants were newly diagnosed IBS and 12 had over two-year disease history. Participants had no problem in EQ-5D survey, some expressed difficulties in dimensions of pain/discomfort and anxiety/depression. Mean utility derived from SG (0.85Ϯ0.16), EQ-5D index (0.79Ϯ0.15) and EQ-5D VAS (0.59Ϯ0.17) were significantly different (pϽ0.05). SG utility was significantly associated with unsubtyped IBS and whether the IBS was newly diagnosed (pϽ0.05). CONCLUSIONS: IBS is well-tolerated but causing problem in anxiety/depression and pain/discomfort in QoL survey. Mean utility of SG is higher than results derived from EQ-5D and EQ VAS, and this finding matches previous literature. Further validate the utility measures in more IBS patients with various subtypes and severity is needed. 
HT4 HEALTH TECHNOLOGY ASSESSMENT MAP IN ASIA -REGIONAL VERSUS INTERNATIONAL INFLUENCES
PODIUM SESSION II: PREFERENCE-BASED OUTCOMES STUDIES PR1 DOES MEDICATION ADHERENCE CORRELATE WITH HEALTH-RELATED QUALITY OF LIFE? FINDINGS FROM A DESCRIPTIVE ANALYSIS
PR3 UTILITY VALUES FOR CHEMOTHERAPY-RELATED ADVERSE EVENTS: A REVIEW OF THE LITERATURE
OBJECTIVES:
Chemotherapy offers cancer patients the potential benefits of improved mortality and morbidity but may cause detrimental outcomes due to adverse drug events (ADEs) that could require time-consuming, resource-intensive and costly clinical management. To appropriately assess chemotherapy agents in an economic evaluation, the impact of ADEs could be included in terms of their incidence, costs of their management and valuation of the perceived disbenefits via (dis)utility of ADEs. This review aimed to identify published studies reporting utility values for chemotherapy-related ADEs. METHODS: A structured electronic search combining terms for utility, utility valuation methods and generic terms for cancer treatment was conducted in MEDLINE and EMBASE in June 2011. Inclusion criteria were: 1) primary data, and 2) elicitation of utility of chemotherapy-related ADE. Two reviewers identified studies and extracted data independently. Any disagreements were resolved by a third reviewer. RESULTS: Eighteen studies met the inclusion criteria from the 853 abstracts initially identified, collectively reporting 218 utility values for chemotherapy-related ADEs. All eighteen studies used short descriptions (vignettes) to obtain the utility values. Of the 218 utility values, 178 were elicited using SG or TTO while 40 were elicited using VAS. 
The current study is to quantify the burden of neuropathic pain (NeP) with respect to health status, work productivity loss, and health care resource utilization among patients in Japan. METHODS: The 2010 Japan National Health and Wellness Survey (NHWS), a self-reported, Internet-based survey of adult Japan population, was used as the data source for this study (Nϭ25,000). All respondents were categorized as those reporting either NeP, a form of pain other than NeP, and no pain. These groups were compared on health status (using the SF-12v2), work productivity loss (using the WPAI), and health care resource use (provider visits, hospitalizations, and emergency room (ER) visits) in the past six months using regression modeling controlling for demographics, health behaviors, and comorbidities. RESULTS: Of the 25,000 patients in Japan, 0.23% (nϭ58) reported experiencing NeP, 5.57% (nϭ1392) reported experiencing another form of pain, and 94.20% reported experiencing no pain in the past month. 
The incidence of cancer is on rise in Malaysia. Despite the existence of different screening methods the response to screening is poor. The current study aims to examine cancer patients' perceptions towards cancer screening and early diagnosis. METHODS: A qualitative methodology was used to collect in-depth information from consented cancer patients, recruited from February to July 2010. After obtaining institutional ethical approval, patients with different types and stages of cancer from the three major ethnic groups (Malay, Chinese and Indian) were approached. Twenty semi-structured interviews were conducted. All interviews were audio taped, transcribed verbatim and translated into English for thematic content analysis. RESULTS: Thematic content analysis yielded four major themes: Awareness on cancer screening, perceived benefits of cancer screening, perceived barriers to cancer screening and cues to action. Majority of the respondents had never heard of cancer screening before the diagnosis. Some accounted of heeding mammogram and pap-smear tests but did not undergo screening due to a lack of personal susceptibility. Those who have had negative results of screening prior to diagnosis perceived such tests as untrustworthy. Lack of knowledge and financial constrains were reported as barriers to cancer screening. Finally, numerous suggestions were given to improve screening behaviour among healthy individuals, including role of mass media in disseminating the message 'prevention is better than cure'. CONCLUSIONS: Patients' narratives revealed some significant issues that were in line with the health belief model which could explain negative health behaviour. The description of the personal experiences with the cancer could provide many cues to action for those who have never encountered this potentially deadly disease if incorporated into health promotion activities. OBJECTIVES: Rural patients in China requiring cardiac and vascular interventional treatment typically have to travel to an urban "tier3" hospital for treatment instead of using their local "tier2" hospital due to lack of equipment. To understand the economic drivers of improved patient access in China a pilot study was initiated. METHODS: Data were collected on patient numbers, clinical and social groups, insurance type, reimbursement rates, and travel costs as well as distance travelled for a period six months before and after installation of equipment in the tier2 hospital. RESULTS: The hospitals chosen were Fengnan Hospital (tier2) and Gongren Hospital (tier3) in Tangshan City and were only 13KM apart. Tier3 hospital patients are reimbursed 55%, 65% and 80% for rural patients (43%), urban resident (29%) and urban workers (18%) respectively. 10% of patients are not covered by insurance and pay all costs. Tier2 hospital patients are reimbursed 70%, 75% and 85%. In the tier3 hospital during the 6 months before the equipment was installed, 1700 patients were treated at an average cost to the patient of 2905 CNY. In tier 2 hospital in the six months following installation, 107 patients were treated at an average cost of 1925 CNY/patient, saving 980 CNY direct cost per patient or 34%. In addition travel costs were reduced by 31 CNY/patient. CONCLUSIONS: The variation in reimbursement strategy for tier2 and tier3 hospitals offer the best financial opportunity for improving access to treatment for patients, however further work is needed to compare regional differences and also the effect of patients having to travel greater distances.
PHP2 ECONOMIC COST SAVINGS OF TECHNOLOGICAL IMPROVEMENT FOR LOWER-LEVEL HOSPITALS: A PILOT STUDY IN CHINA
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